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Expanded Abstract 
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Hypothesis 
Afelimomab, a fragment of murine monoclonal antibody to 
human TNF-α, reduces 28-day all-cause mortality in 
patients with severe sepsis and elevated serum IL-6 levels. 
Methods 
Design: Prospective, randomized, double-blind, placebo-
controlled, multi-center, phase III clinical trial. 
Setting: One hundred fifty-seven intensive care units in the 
United States and Canada. 
Subjects: 2,634 patients with severe sepsis secondary to 
documented infection, of whom 998 had elevated IL-6 
levels. 
Intervention: Patients were stratified into two groups by 
means of a rapid qualitative interleukin-6 test kit designed to 
identify patients with serum interleukin-6 levels above (test 
positive) or below (test negative) approximately 1000 
pg/mL. Of the 2,634 patients, 998 were stratified into the 
test-positive group, 1,636 into the test-negative group. They 
were then randomly assigned 1:1 to receive afelimomab 1 
mg/kg or placebo for 3 days and were followed for 28 days. 
The a priori population for efficacy analysis was the group of 
patients with elevated baseline interleukin-6 levels as 
defined by a positive rapid interleukin-6 test result. 
Outcomes: The primary outcome was 28-day all-cause 
mortality. Secondary outcomes included improvement in 
organ dysfunction, reduction in TNF and IL-6 levels, and 
safety. 
Results 
In the group of patients with elevated interleukin-6 levels, 
the mortality rate was 243 of 510 (47.6%) in the placebo 
group and 213 of 488 (43.6%) in the afelimomab group 
(p=0.21). Using a logistic regression analysis, treatment 
with afelimomab was associated with an adjusted reduction 
in the risk of death of 5.8% (p = .041) and a corresponding 
reduction of relative risk of death of 11.9%. Mortality rates 
for the placebo and afelimomab groups in the interleukin-6 
test negative population were 234 of 819 (28.6%) and 208 
of 817 (25.5%), respectively (p=0.16). In the overall 
population of interleukin-6 test positive and negative 
patients, the placebo and afelimomab mortality rates were 
477 of 1,329 (35.9%)and 421 of 1,305 (32.2%), respectively 
(p=0.049). Afelimomab resulted in a significant reduction in 
tumor necrosis factor and interleukin-6 levels and a more 
rapid improvement in organ failure scores compared with 
placebo. The safety profile of afelimomab was similar to that 
of placebo. 
Conclusion 
Afelimomab is safe, biologically active, and well tolerated in 
patients with severe sepsis, reduces 28-day all-cause 
mortality, and attenuates the severity of organ dysfunction in 
patients with elevated interleukin-6 levels. 
Commentary 
Sepsis and multiple organ dysfunction syndrome are 
leading causes of morbidity and mortality in the ICU [2]. 
Modulating the endogenous host inflammatory response 
toward the goal of improving survival for septic patients has 
been the holy grail of critical care researchers for some Critical Care   October 2005 Vol 9 No 5   Rondon and Venkataraman 
time. Nearly sixty randomized controlled clinical trials have 
been conducted in this area, yet no new agents have been 
introduced into clinical practice [3]. In multiple studies of 
anti-TNF-α therapies, there have been no statistically 
significant improvements in survival in the experimental 
cohorts; indeed, in at least one study, survival was actually 
worsened in the group receiving the new agent. A meta-
analysis of these trials suggested a small, but significant 
benefit for anti-TNF-α agents [3]. 
It is upon this background that we consider the study by 
Panacek and colleagues [1]. Their study is unique in that it 
is the first cytokine-based antisepsis trial to target specific 
subgroups of septic patients on the basis of a biochemical 
marker (serum IL-6 concentration). Increased IL-6 levels 
correlate with severity of illness and are associated with a 
poor outcome in septic patients. TNF-α is a proximal 
stimulus for IL-6 release. Hence, patients with elevated IL-6 
levels could potentially benefit from an anti-TNF-α 
approach. 
In this study, 2634 patients with severe sepsis were 
randomized to a 3-day course of afelimomab, a fragment of 
a murine monoclonal antibody to human TNF-α, or placebo. 
Prior to randomization, patients were classified as having 
either high (>1000 pg/ml) or normal serum IL-6 
concentration via a rapid qualitative bedside assay. The 
primary a priori population for efficacy analysis was the 
subgroup of patients with elevated IL-6 levels (n=998). The 
authors found that mortality was lower in the high IL-6 
patients that received afelimomab (43.6% versus 47.6%, 
p=0.21), though this difference only achieved statistical 
significance after adjusting for subtle baseline differences 
between groups. There were no differences in adverse 
events between groups, but human anti-mouse antibodies 
formed in nearly one quarter (23.6%) of afelimomab-treated 
patients. The authors concluded that afelimomab was safe 
and reduced mortality in septic patients with elevated IL-6 
levels. 
This study has a number of strengths. It is the largest 
prospective, multi-center, double-blind, randomized 
controlled trial in severe sepsis completed to date. Follow-
up was complete in all patients and co-interventions, such 
as adequate antibiotic therapy, surgical interventions, and 
other supportive care, were similar between groups. By 
focusing on patients with elevated IL-6 levels, the authors 
selected a group at high risk of mortality, and by extension, 
the group with arguably the most to gain from treatment. 
A few limitations of this study deserve consideration. First, 
randomization failed to balance some clinically relevant 
factors among groups. For instance, sequential organ failure 
assessment (SOFA) scores trended higher in subjects that 
received active drug (11.2 vs. 10.8, p=0.058). Differences in 
baseline characteristics likely explain why the improvement 
in mortality seen with afelimomab was only significant after 
multivariable modeling, though it would have been helpful 
for the authors to have provided more details about these 
models. Second, the mortality benefit of afelimomab was 
small relative to that seen with another recent addition to the 
sepsis armamentarium, drotrecogin alfa (activated) [4] 
(relative risk reduction, 11.9% vs.19.8%) [5]. Conceivably, a 
combination of these two agents might yield even greater 
reductions in mortality. Third, while no clinical sequelae 
were associated with the development of human anti-mouse 
antibodies, the frequent occurrence of these antibodies 
raises concern about the future use of other antibody-based 
therapies, such as abciximab, in these patients. Fourth, 
there are questions about the practicality of rapid IL-6 
testing at the bedside in routine clinical practice. Finally, the 
results of this trial, which completed enrollment June 1999, 
were not published until November 2004. Delayed 
manuscript rejections and a change in the company owning 
the product and their internal review process were some of 
the circumstances that led to this unfortunate delay (Ed 
Panacek, personal communication). 
Recommendation 
Afelimomab appears to be safe and may improve mortality 
in the subset of septic patients with high IL-6. However, 
outside the setting of randomized clinical trials, we cannot 
recommend its routine use. Further study is needed to 
determine if addition of afelimomab to already existing 
proven therapies, such as drotrecogin alfa (activated) or 
steroids [6], leads to additional mortality benefits in severe 
sepsis. 
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